Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Rifapentine and Isoniazid on Tenofovir Alafenamide PK
NCT03510468Phase 1Completed
- Sponsor
- National Institutes of Health
- Start
- Jun 2018
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by National Institutes of Health. Primary endpoints: Plasma Area Under the Curve During the Dosing Interval of 0 to 24 Hours, Maximum Total Plasma Concentration at Day 31 and 4 more. Started Jun 2018; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03510468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03510468.